BerGenBio to present NSCLC and AML clinical data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019
- Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA
- Accepted for presentation at ASCO in June 2019
Bergen, Norway, 23 April 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that the Company and its collaborators will present new interim clinical and biomarker data from its extensive Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago, Illinois (31 May - 4 June 2019).
Abstract titles have been announced online at https://iplanner.asco.org/am2019/ and details of the presentations are below.
The posters presented at ASCO will be made available on www.bergenbio.com in the Investors / Presentations section at time of presentation.
Sunday 2 June, 8:00 AM – 11:00 AM Central Daylight Time
A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.
- Enriqueta Felip et al
- Session: Lung Cancer – Non-Small Cell Metastatic
- Location: Hall A, poster board #421, abstract 9098
Monday 3 June, 8:00 AM – 11:00 AM Central Daylight Time
First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML pts unfit for intensive chemotherapy: Phase II open-label study.
- Dr Sonja Loges et al
- Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
- Location: Hall A, poster board #418, abstract 7043
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focussed on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody is undergoing Phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Jessica Hodgson, Chris Welsh, Nicholas Brown, Carina Jurs, Consilium Strategic Communications
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.